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Abstract 
Automated technologies have revolutionised the monitoring of coagulation disorders in the 
central hospital laboratory setting, allowing for high throughput testing, improved accuracy 
and precision, accompanied by a marked reduction in human error. However, they still 
require trained operators and sample transportation. With the advent of point of care (POC) 
testing, the working principle of traditional coagulometers was used as the foundation for the 
development of miniaturised devices. A number of POC coagulation devices have been 
commercially available for many years now, allowing the patient to assume more control 
over the management of their own medication, e.g. warfarin. While POC devices for 
measuring anticoagulation have relied principally on clotting time tests, novel platelet 
function tests, and factor-specific assays based on enzymatic or immunoassay principles are 
becoming available, driven by the emergence of new anticoagulant drugs, in addition to the 
inability of clotting tests to accurately detect many thrombotic disorders. This review 
highlights recent progress in the development of POC coagulation monitoring technologies 
and examines their future potential in clinical diagnostics. 
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1. The development of central laboratory coagulation testing 
 
The monitoring of bleeding disorders has been in existence for around 3000 years with the 
first bleeding time test described by the Chinese emperor Huang Ti, as the length of time that 
blood flows from the skin after rupture. The bleeding time was also described by Sydenham 
at the turn of the 17
th
 century, but it was not until the 1900s when disorders of the clotting 
system were detected using bleeding time at the bedside [1].  
  
While comparatively more sophisticated in their mode of operation, many coagulation tests 
still use the same principles since their discovery in the early 19
th
 century, where it was found 
that blood coming into contact with glass containers or various biological tissues such as 
placenta accelerated its clotting [1,2]. The development of the understanding of the 
coagulation cascade and the interaction of various factors led to the development of the first 
clotting time tests (Fig. 1). These tests now principally include the Prothrombin Time (PT) 
test, which measures the tissue factor-induced clotting time of plasma [3], the activated 
Partial Thromboplastin Time (aPTT), one of the most frequently requested screening tests for 
monitoring unfractionated heparin (UFH) therapy [4, 5], the Activated Clotting Time (ACT), 
currently used to monitor anticoagulation in patients undergoing cardiopulmonary bypass 
(CPB) and are receiving high doses of UFH [5], and the Thrombin Time test (TT), a simple 
assay measuring the conversion rate of fibrinogen to insoluble fibrin after the addition of 
thrombin to plasma [6]. Changes from the normal clotting times of these assays may result 
from changes in active coagulation factor concentrations due to genetic factors, disease or 
injury, or through the administration of anticoagulant drugs. 
 
Initially, assay methods were based on the visual detection of a clot, either through 
observation of fibrin strands, or detection of bulk changes in viscosity [2,3,7] (Fig. 2). The 
level of automation involved was typically around controlling the mixing and interaction of 
the sample with the clotting reagents or surface contact with glass. Progressively, visual 
detection of clot formation was replaced by optical detection technologies, using 
turbidimetric [1] and nephelometric [8] techniques in which the change in optical density of 
the sample resulted from the formation of the fibrin network. Mechanical detection also 
replaced visual detection in which the change in viscosity was detected, for instance by the 
cessation of the movement of a steel ball in the rotating sample tube which could be detected 
optically [9]. This level of automation led to many advantages over manual testing, such as 
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high volume testing, better reproducibility due to strict quality control programs, increased 
user flexibility, and cost reductions.  
 
Coagulation instruments based on optical detection of clot formation could also be made 
compatible with the need for other assays applicable to haemostasis. This was particularly 
useful for the measurement of the activity of coagulation factors. These factors are typically 
serine protease enzymes that transform an inactive zymogen into its active form. The 
development of chromogenic substrates that, when cleaved would release a chromophore 
now allowed enzymatic factor assays to be performed alongside traditional coagulation tests 
on a single instrument platform [10]. Other systems developed modified latex agglutination 
assays to perform immunoassays, again exploiting principles such as turbidimetry [11,12]. 
This has been further refined through the use of particle proximity assays in which the close 
proximity of two particles due to a binding interaction, results in a signal from one of the 
particles. For example, in the Luminescent Oxygen Channelling Immunoassay (LOCI) the 
photoactivated formation of short-lived singlet oxygen on one particle is then capable of 
inducing chemiluminescence on a neighbouring particle when bound together via an 
antibody-antigen interaction [13]. A number of popular commercial central hospital 
coagulometers and their characteristics are listed in Table 1. 
  
2. The development of point of care coagulation testing 
 
The need for point of care (POC) coagulation technologies became necessary as centralized 
laboratories became increasingly unable to provide results in the time frames required to 
allow rapid turnaround which would allow timely intervention of anticoagulant therapy [14]. 
This was equally so for inpatients requiring dosage adjustment during emergency procedures 
or for outpatients to allow dosage adjustment before leaving the clinic. Such improvements 
were thus necessary to improve patient satisfaction and improve clinical outcome [5]. 
 
While the initial costs of POC testing may be greater, the wider patient, economic, and 
societal benefits offered by the implementation of such programs cannot be ignored. In a 
recent review [15], the effects of POC coagulation testing on the rate of perioperative 
transfusion of allogenic blood products, the frequency of hemostatic treatment, and the 
clinical outcome were assessed. While POC treatment is limited, the implementation of such 
programs may potentially reduce rates of transfusion and lower costs associated with 
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hemotherapy. Lee-Lewandrowski et al. [16] looked at the impact of a POC testing program in 
a large academic medical centre where over 500,000 tests are performed annually, ranging 
from glucose and creatinine testing, to ACT and D-dimer analysis. According to their report, 
the majority of POC tests was actually performed to improve clinical operations and to aid in 
capacity management of the hospital facilities, and not out of medical necessity. Thus, 
improvements were observed in clinical operations rather than clinical outcomes. A similar 
trend was observed with studies for cardiac markers in emergency department settings, where 
the length of stay for patients was significantly reduced but with little improvement in clinical 
outcome [17]. Nichols et al. [18] monitored the clinical outcomes of POC testing in the 
cardiology setting, and while rapid results were achieved, the impact on patient care was not 
obvious.  
 
Goodnough & Hill [19] have highlighted the need for POC coagulation testing in clinical 
settings including liver transplantation, cardiothoracic surgery, and trauma because of the 
high risk of hemorrhage and the resulting requirements for blood component support. Other 
research has identified that POC testing in the form of platelet count, PT, aPTT and 
fibrinogen concentration has resulted in reduced blood loss, shorter surgical times, and 
reduced transfusion requirements [20,21]. Asimos et al. [22] conducted a study on trauma 
patients and determined that taking POC blood measurements such as haemoglobin resulted 
in reduced morbidity. While clinical outcomes reporting morbidity and mortality indices will 
give a greater indication of the effectiveness of various POC assays, this data will take a long 
time to accumulate. 
 
2.1. POC clotting time tests 
 
Given the importance of clotting time tests such as PT, aPTT and ACT in the central 
laboratory setting, these were, unsurprisingly, the first tests to undergo significant 
development and conversion to POC type platforms [18]. One major driver was the need to 
have rapid information in the operating theatre on blood coagulation status. The first POC 
instruments were thus simple, bench top versions of earlier coagulometers, often employing 
the same principles. For example, the Hemochron® Response system (ITC, USA) employed 
the Hall effect in which the clotting of the blood sample caused a small magnet to rotate with 
the sample in the tube, and so changing the magnetic flux of an external electromagnet [23] 
(Fig. 3a). This is still widely used to perform ACT measurements for high dose heparin 
 6 
anticoagulation in major surgeries. The device was gradually equipped with two sample tubes 
due to the fact that full anticoagulation requires several hundred seconds of measurement 
time. Thus, assays could be performed alternately to ensure a timely result. The Actalyke® 
XL and Actalyke® Mini II (Helena Laboratories Point of care, USA) use a related principle 
of operation in which two magnetic sensors are used to detect the movement of a magnet 
inserted in the ACT tubes [24]. These two sensors, one at 0º and the other at 90º, 
independently sense the magnet in the ACT tube. As the clot begins to form, it displaces the 
magnet in the test tube. When the magnet reaches a fixed distance between the two detectors 
(i.e. approximately 46º away from detector at 0º), the system returns the ACT clot time [25]. 
 
Until the 1950s, anticoagulant treatment could only be given parenterally in the form of 
heparin, which limited its use to the hospital setting [26]. The introduction of warfarin as an 
oral anticoagulant allowed the continuous treatment of those at risk of venous 
thromboembolism and is still one of the top 40 most prescribed drugs in the USA [27]. 
However, coumarin has quite unpredictable dose-response characteristics and has a relatively 
narrow therapeutic window, leaving patients at an elevated risk of bleeding or clotting [28]. 
This resulted in a major drive to develop devices that could be used in primary care settings 
such as clinics, by GP surgeries, or even by the patient themselves to allow the more precise 
control and adjustment of dosage. In the early 1990s a POC device for monitoring warfarin 
treatment was introduced by Boehringer Mannheim (now part of Roche Diagnostics) called 
the CoaguChek®, which was capable of performing PT measurements. The device used a 
simple, disposable microfluidic strip in which a whole blood sample taken by fingerstick was 
combined with a thromboplastin reagent in the presence of small iron filings [29]. These 
filings could be induced to move by the application of an electromagnetic field and this 
movement was then detected optically (Fig. 3b). The cessation of movement as a result of 
coagulation can be detected as the clotting time. This device was also capable of measuring 
PT using the International Normalized Ratio (INR) which allowed the standardization of PT 
assays based on World Health Organisation reagents and assay methodologies [30]. Thus, an 
INR from one device could be reliably compared to the value determined on another. Before 
the introduction of INR, all PT clotting times were specific for the reagents and test device 
used. This is still the case, however, for other coagulation tests such as aPTT, for which no 
international standard has been established. 
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Other POC devices for PT/INR have persisted with the mechanical approach to clot 
formation. For instance, The Coag-Sense™ PT/INR monitoring system (CoaguSense Inc., 
USA) is based on a test strip with a rotating, spoked wheel that draws the sample into the 
reaction well. The spokes rotate across the path of an infrared light beam and mixes the liquid 
sample with recombinant rabbit thromboplastin which is dried in the reaction chamber. When 
the sample clots, the spokes simply lift the fibrin clot from the reaction well and the 
interruption of the light beam is measured by an optical detector. The PT is reported as the 
time between the introduction of blood onto the test strip and blockage of the light beam in 
seconds [31]. The manufacturer states that as it is a direct mechanical measurement, results 
are not affected by low hematocrit levels or by the concentration of blood constituents, 
resulting in more precise and reliable results [32]. While the assay only requires 10 µl of 
sample, the instrument itself is more bench top than hand-held or portable. 
 
While there are now numerous devices available for self-testing of PT/INR in association 
with warfarin therapy, other coagulation tests such as aPTT and ACT have remained for 
professional use only. There are several devices that can perform panels of clotting time 
measurements in a small, portable device, with accompanying reductions in required sample 
volumes, materials and reagent costs through the development of disposable polymer chip-
type technologies. For example, in the Hemochron® Signature, 15 µl of whole or citrated 
blood is added to a polymer microfluidic test cartridge containing coagulation reagents (Fig. 
3c). The sample and reagents are mixed with the aid of pumps within the instrument. This 
mixing homogenises the sample and reagent and ensures even clotting of the sample. The 
mixture is then moved back and forward within the channel which is monitored by a series of 
LEDs. Cessation of movement due to clotting is again detected optically. These devices 
which again rely on cessation of movement due to clot formation can typically form a panel 
of assays for PT/INR, aPTT and ACT. 
 
2.2. POC methods and devices based on thrombin activity 
 
As was discussed in the context of central hospital laboratory haematology, chromogenic 
assays have been used to measure the enzymatic activity of specific clotting factors through 
the development of artificial, cleavable peptide substrates specific for particular factors. It 
should be noted that assays based on clotting time such as aPTT, PT and ACT are essentially 
functional measures of thrombin formation and its inhibition in the presence of anticoagulants 
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such as warfarin and heparin. Thus, an analogy can be drawn between assays based on the 
measurement of fibrin formation and assays based directly on the measurement of thrombin 
activity via the use of appropriate peptide substrates such as in chromogenic assays.  
 
The electrochemical behaviour of blood has been studied since 1928 [33,34]. Electrochemical 
detection involves the use of a working and a reference electrode, whereby a constant 
potential is applied to the working electrode leading to an oxidation-reduction reaction that 
can be quantified as a recordable electric current [35,36]. Electrochemical sensors have found 
widespread use in the development of POC and self-test devices, as exemplified by the 
development of glucose test strips as they are simple to interface with electronic instruments 
and reduce device costs. Devices such as the CoaguChek® XS (Roche Diagnostics) and the i-
STAT® (Abbott Diagnostics) have both employed electrogenic substrates which result in the 
formation of an electrochemically detectable cleavage product which is proportional to 
thrombin activity. These devices then return a clotting time rather than a measure of thrombin 
activity to allow comparisons with standard clotting tests. However, while the i-STAT® is 
targeted at professional use and can perform PT/INR and ACT, the CoaguChek® is targeted 
at the self-test market for PT/INR (Fig. 4a). 
 
INR values of 52 patients receiving oral warfarin were measured using the i-STAT® PT/INR 
and the CoaguChek® XS Plus and compared with those obtained using the reference 
laboratory instrument from Diagnostica-Stago (France). Considering the results obtained, 
INR measurements generated using the CoaguChek® XS Plus correlated better with the 
Stago system than the results generated using the i-STAT® PT/INR [37]. However in a more 
recent study, Challen et al. [38] evaluated the impact that close monitoring using the i-
STAT® had on outcomes of patients on anticoagulant treatment. Their positive results 
showed that implementation of the i-STAT® POC machine in a pharmacist-managed 
anticoagulation clinic increased the proportion of time within therapeutic INR range by 9.9%. 
In addition, safety, adherence and cost were improved, indicating potential for 
implementation on a larger scale in the future.  
 
As well as devices that use electrochemical analogies to available chromogenic tests such as 
the iSTAT® and the CoaguChek® XS, some have attempted other direct means of 
electrochemical measurement. In some cases, the change in the steady state current is related 
to a change in sample viscosity [39] and in others, the cleavage of an amperogenic substrate 
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leads to an electric current flow which can, for example, relate to thrombin generation [36]. 
One of the advantages of electrochemical detection is that sample colour/turbidity and the 
presence of clots or platelets do not affect the measurement [36]. 
 
The Alere (formerly HemoSense) INRatio® is a disposable polymer strip with screen printed 
silver paste electrodes in combination with PT assay reagents [40]. Application of the whole 
blood to the strip and activation of coagulation is monitored using electrochemical 
impedance. This technique is sensitive to a number of physical and chemical characteristics 
of the sample. Electrochemical impedance measures both capacitive and resistive 
characteristics of the material in contact with the electrode. Blood is a complex mixture of 
ionic species, insulating biomolecules and interfaces such as membranes which all contribute 
to its electrochemical impedance properties. In addition, these characteristics also change 
over time due to the movement of cellular species, formation of the fibrin network and the 
trapping of cells, platelets and plasma within this matrix. As a result, changes in the 
resistance of the coagulating blood can be detected which can be related to the clotting time. 
The INRatio® is also currently used for self-test measurement of PT/INR (Fig. 4b). 
 
Most POC tests for measuring thrombin activity have been based on in vitro methods. 
However, in vivo methods for thrombin measurement have the potential to yield further 
information as to its role at the vascular level. Campbell et al. [41] employed laser scanning 
confocal microscopy (LSCM) to observe in situ thrombin generation, where it has been seen 
to form a fibrin network more rapidly, densely and in a manner more resistant to lysis than in 
vitro. Such knowledge can be used to determine targets for anticoagulant therapy, which can 
either prevent thrombosis or stabilize fibrin clots, thus preventing embolism. The role of 
thrombin in atherosclerosis has also been studied using intracellular fluorescent probes of 
thrombin activity used in combination with in vivo fluorescence imaging [42]. Other in vivo 
studies of thrombin have employed microenzyme immunoassay to measure thrombin-
antithrombin complex (TATc) levels, and correlated these against images of atherosclerotic 
plaques using non-invasive computed tomographic angiography [43]. Such studies have 
indicated that in vivo thrombin generation is independently related to the occurrence and 
severity of coronary artery disease. 
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2.3. Immunoassays for POC coagulation testing 
 
While other assay types such as chromogenic and immunoassay were readily integrated into 
laboratory-based coagulometers, development of such assays in the POC sector has been 
principally through stand alone platforms for a number of critical analytes. One of the key 
analytes is D-dimer which is used to diagnose thrombosis or disseminated intravascular 
coagulation (DIC) [44]. D-dimer is formed as a result of the breakdown of a clot following 
fibrinolysis and is typically measured using immunoassay. The Triage® system (Alere, USA) 
uses a microfluidic cartridge with capillary structures to meter the volumes of blood used in 
the assay, and a series of reaction areas in which the sample mixes with immobilised reagents 
for defined time periods. Here, the D-dimer binds to a labelled antibody which is in turn 
captured at a capture site downstream forming a coloured line. The Triage® is an example of 
a lateral-flow type immunoassay converted to a polymer microfluidic platform. In a study on 
a number of POC D-dimer assay platforms, Geersing et al. [45] showed that while there were 
variations in their ease of use all platforms exhibited comparable accuracy. 
 
While clotting factor deficiencies have traditionally been diagnosed using conventional 
clotting assays, immunological tests are more suited to the study of hereditary thrombotic 
states or predisposition such as protein C, protein S, antithrombin and tests for evidence of 
DIC including fibrinogen degradation products (FDPs), fibrinogen, and D-dimers [46]. Most 
POC devices use antibody-antigen binding technologies as they allow for assay specificity 
and sensitivity and are versatile in the detection methodology that can be used such as 
fluorescence, time resolved fluorescence or turbidimetry [47]. On the other hand, 
immunoassays are often time consuming and depending on the specificity of the assay, the 
antibodies of choice can be expensive. Sensors based on immunoassays often have difficulty 
competing with traditional immunoassays which typically demonstrate greater sensitivity. 
However, they do hold promise for testing where sensitivity can be sacrificed for improved 
ease of use and faster time to result, such as in near-patient setting [48]. 
 
2.4. Resonant transducers 
 
What is clear from the earlier discussion is that a large number of coagulation tests have 
exploited the change in viscosity that results from clot formation. Initially, this was achieved 
using slow, bulk methodologies. However, the tilt tube test introduced an important principle 
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which has been further refined and applied to coagulation testing, which is the application of 
an oscillatory force to the system. This was enhanced in other devices such as the 
Hemochron® Signature in which the sample was pumped backwards and forwards to 
enhance and detect clotting. In an extension of what is essentially a form of oscillatory 
rheometry, other systems such as the Thromboelastograph® (TEG®, Hemonetics Corp.) and 
ROTEM® (Tem International, GmbH) have used the application of an oscillating sheer force 
to measure the resulting sheer stress in a time-dependent manner during coagulation [2,49]. 
These technologies have found favour particularly among anaesthesiologists as they provide 
complex but detailed information on patient clotting status and fibrinolysis. For instance, 
TEG® traces can show clotting times, rates of clot formation, and overall clot strength. These 
parameters contain vital information as to levels of clotting factors, platelets, and fibrinogen 
concentration. However, due their size and complexity, oscillatory rheometry has not 
transitioned into wider POC application and acceptance. 
 
Several miniaturized resonant transducer systems have been applied to blood coagulation 
measurement. Devices such as the quartz crystal resonators are also sensitive to changes in 
viscosity of a material in contact with its surface. These devices typically operate at high 
frequencies (10-20 MHz) and their penetration depth into the sample is only on the order of 
100-200 nm. They have been extensively investigated for their ability to monitor blood 
coagulation. However, the cost of quartz crystal resonators makes it prohibitive as a single 
use disposable device, while re-use is made challenging as biomaterials such as fibrin adhere 
extremely well to the gold electrode surface and are very difficult to regenerate effectively. 
Others are now employing alternative microresonators based on MEMS technologies. One 
such system is the disposable SmartStrip® developed by Microvisk Technologies Ltd (UK) 
[50]. Microvisk uses MEMS blood sensors on a disposable strip, which incorporates two 
microcantilevers to measure changes in viscosity of the blood over time. One measures blood 
thickness, while the other one detects background vibrations that are subtracted to provide a 
better signal. The cantilevers are comprised of several layers of materials: plastic (two 
polyamide strips), heaters and sensors (piezo-resistive element). The heater and the piezo-
resistive element are located between the two polyamide layers which have different 
coefficients of expansion. With an increase in temperature, the cantilevers vibrate while the 
piezoelectric generates a small current that indicates how much they flex. When a drop of 
whole blood taken by a finger prick reacts with the dried thromboplastin stored on the strip, 
the blood starts to coagulate. This change in viscosity is sensed by the cantilevers and 
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transmitted to the piezo-resistive layer indicating the coagulation endpoint [50–52]. These 
devices can be mass-manufactured at low cost, which is an essential requirement for single 
use disposability. 
 
Table 2 summarizes the characteristics of 23 commercially available POC coagulation 
analyzers [5,14,25,53,54,55]. 
 
2.5. POC tests for platelet function 
 
With the increase in understanding of the role played by platelets in arterial thrombosis, 
growing numbers of patients are being treated with platelet inhibitors (e.g., aspirin) and other 
non-steroidal anti-inflammatory drugs, thienopyridine derivatives (e.g. ticlodipine, 
clopidogrel) and GP IIb/IIIa receptor antagonists (e.g. tirofiban, Abciximab) [54,56]. 
Treatment with these antiplatelet drugs has enhanced the need to monitor their effects in 
order to avoid bleeding and thrombosis. Platelet testing was traditionally based on platelet 
aggregometry. However, such tests do not represent physiological conditions [57,58]. Several 
novel platelet function tests have been developed to assess platelet function and the impact of 
antiplatelet therapies at the POC [5,25,53,57] (Table 3). One of these, the VerifyNow® 
(Accumetrics, USA) is essentially a form of miniaturised light transmission aggregometry 
performed in a disposable cartridge. The level of aggregation is sensitive to a number of 
antiplatelet therapies [59]. However, such devices again do not fully take into consideration 
the complex nature of platelets and their interactions with soluble clotting factors, surfaces 
and each other [60], resulting in the lack of test standardization in the assessment of 
antiplatelet therapy [54,61].  
 
3. Future perspectives 
 
While there have been many technological advances in coagulation testing in the last one 
hundred years or so, many technologies are still measuring changes in bulk viscosity, or use 
other relatively simple principles such as enzyme activity or particle aggregation. However, 
the drive for POC has also driven technological solutions which can operate at the microscale 
and many such innovations have been implemented in the available commercial technologies. 
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While there is quite an array of devices for performing clotting time tests, there still remains 
the need to improve and refine the way clotting end points are determined. Table 4 outlines a 
selection of novel technologies from the research literature [36,62–68]. At present, the 
clotting time is a relatively arbitrary point at which the burst in thrombin production leads to 
an exponential rise in fibrin formation. It is this rapid change that is assigned as the clotting 
time. However, the precise onset of this process is highly unpredictable. In a large, bulk 
sample, initiation of coagulation processes may take place at different times and different 
locations, leading to an inherent imprecision in the derived clotting time value. The ACT test 
for example, has been shown to be highly variable for use in patients undergoing 
cardiopulmonary bypass in instances of hypothermia and haemodilution, resulting in the 
unreliable assessment of anticoagulation [69]. Dudek et al. [63] developed a microstructured 
microfluidic device for performing an aPTT assay that analysed clot formation at the 
microscopic level using a fluorescent fibrinogen label. They found that clotting time could be 
determined by monitoring the distribution of clot formation using the fluorescence generated 
from the incorporated labelled fibrin. This led to very precise measurement of clotting time, 
as well as a much wider dynamic range for heparin measurement beyond the range typically 
used in conjunction with aPTT and normally requiring ACT.  
 
There is also a demand for novel POC assays for haemostasis. Some of this relates to the fact 
that many standard tests have not yet translated into POC formats such as routine tests for 
thromboembolic complications that can detect factor V Leiden, lupus anticoagulant, protein 
C, protein S, and AT deficiency [70]. There is also a gradual move away from traditional 
anticoagulant drugs such as warfarin and heparin due to their unpredictable pharmacokinetic 
properties. This presents two challenges for coagulation testing. The first is whether there 
will be a continuing need to monitor the effects of these new drugs, given their much 
improved and more predictable characteristics and, the second is how they can be tested if 
this is necessary. Already, clinical guidelines of the monitoring of novel anticoagulant 
therapies are demonstrating that while the requirement for testing may be reduced, it will still 
be necessary for atypical patients such as pregnant women, children, under- and overweight 
people and people with renal dysfunction. In addition, low molecular weight heparins cannot 
be effectively monitored using current clotting time tests as these are predominantly based on 
thrombin formation. Low molecular weight heparins have far less impact on thrombin, but 
exert their control in the preceding step in the coagulation cascade where they primarily 
inhibit Factor Xa activity. Thus, tests for Factor Xa at the point of care may become 
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increasingly important. A novel fluorogenic anti-FXa assay was developed for monitoring 
low molecular weight heparins by Harris et al. [71]. The assay was further developed and 
modified and the ability to measure the concentration of both unfractionated and low 
molecular weight heparin anticoagulant drugs in plasma was demonstrated using a polymer 
microfluidic device (unpublished data).  
 
As with the emergence of the laboratory-based coagulometers, the ability to perform multiple 
assay types on a single platform is also an increasing driver for POC devices. This means 
that, where possible, the assays must share a common transduction mechanism. For example, 
Aizawa et al. [72] developed an immunosensor for measuring fibrinogen and fibrin-
degradation products based on quartz crystal resonator employing a latex agglutination assay. 
In the presence of fibrin degradation products and latex beads with immobilised antibodies, 
agglutination at the surface of the quartz crystal brought about a measurable change in 
resonant frequency. Such an assay could share a common microresonator platform with clot-
based assays using a commercially viable MEMS-based technology. 
 
While attempts to improve POC testing are currently focussed on the development of low-
cost miniaturised devices [73], Giljohann and Mirkin [74] suggested that new materials such 
as nanostructures, present attractive properties for the development of miniaturized 
biodevices such as controllable size-dependent properties, adaptable chemical composition, 
and chemically and physically robust structures. Polyvalent nanoparticles, carbon nanotubes, 
and silicon nanowires are all materials that can allow for the easy translation of a change in 
electrical conductance due to target binding, into a spectroscopic or electrical signal. 
Nanoshells and noble-metal nanoparticles can be modified to recognise biomolecules so that 
they can detect proteins, elemental ions, and small molecules. Such strategies allow 
adaptation for many analyte types and due to the properties of nanostructures, they can be 
easily manipulated providing excellent versatility and increased sensitivity. Label-free 
technologies such as the microsphere resonator biosensor for thrombin measurement as 
developed by Zhu et al. [75] highlight another area of biosensor development that will allow 
for high sensitivity and selectivity with a wide range of biomolecules.  
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4. Conclusions 
 
In the one hundred years since the first clotting time tests were proposed, the development of 
coagulation assay technology has progressed significantly to a point where it now allows 
individuals to assess their own clotting status in the comfort of their own homes. The range 
and the quality of the tests available has also increased significantly, allowing various 
measures of clotting time, platelet function, factor activity, and concentration. These tests 
have progressed alongside an increased understanding of the processes involved in 
haemostasis and the development of anticoagulant drug therapies. Many of these tests are still 
only relevant to professional use applications. Only in the case of PT/INR has coagulation 
testing emerged as a consumer diagnostic product. Nonetheless, many POC platforms now 
exist to facilitate the rapid and convenient measurement of clotting status in all clinical 
scenarios including operating theatres, emergency rooms, in-patient and out-patient settings, 
in the management of a wide range of conditions from the diagnosis of genetic coagulation 
disorders, management of perioperative anticoagulation, in the treatment of thrombosis, and 
for the prophylactic management of a wide range of thrombophilic conditions. 
 
Many new technologies continue to be applied to enhance and refine the ability to perform 
coagulation tests at the POC, primarily focussed on improved systems miniaturisation and 
functional integration. While the technologies being used may be ingenious, the adoption of 
such devices is not without many significant challenges which include the quality, robustness 
and cost of the underlying technology, intellectual property issues, regulatory approval, 
clinical acceptance, the economics of test usage and the ultimate market size. It is not 
surprising then, that much technological development has been predominantly incremental in 
nature. Coagulation testing is also under pressure from improvements in drug treatment that 
claim to not require monitoring. While this may be partially true, the cost and rate of adoption 
of new drugs, coupled to the complexities involved in managing patients with very specific 
medical requirements will ensure that some amount of testing will remain for some time to 
come and that new tests for new drugs may open up new testing opportunities. Certainly the 
challenge of the management of the aging population may also see a continued demand for 
devices suitable for out-patient and self-test use in an attempt to contain ever-increasing 
healthcare spending. It is assumed that further technological development will continue to 
make these cheaper, quicker and simpler to use. 
 16 
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Table 1. Summary of selected laboratory coagulometers 
Coagulometer  Automation  Detection 
Methodology  
Assay Menu  
BCS® XP; Sysmex® 
(Siemens Healthcare 
Diagnostics, USA)  
Full  Chromogenic  
Immunologic  
Photo-optical  
Turbidimetric  
a2-Antiplasmin, Antithrombin, aPTT 
TT, Anti-Xa, Fibrinogen , 
FII;FV;FVII;FVIII;FIX; ,FX; FXI; 
FXII, FV-Leidin, LA, Plasminogen, 
Protein C, PT, UFH, VWF  
 
STA-R® series 
(Diagnostica Stago, 
France)  
Full  Chromogenic  
Immunologic  
Mechanical  
Antiplasmin, TAFI, Antithrombin, 
aPTT 
TT, UFH & LMWH, D-dimer, 
Fibrin, Fibrinogen, LA, 
Microparticles, Plasminogen, Protein 
C & S, PT, VWF  
 
Cascade® series 
(Helena Laboratories, 
USA)  
Semi  Photo-optical  aPTT, ACT, PT, TT  
 
 
 
ACL® 
(Instrumentation 
Laboratories, USA  
Full  Chromogenic  
Immunologic  
Nephelometric  
Photo-optical  
Antithrombin, APC-R, aPTT 
TT, Fibrinogen , D-dimer , 
Homocysteine, LA, FXIII, 
Plasminogen, Protein C & S, PT, TT, 
UFH & LMWH, VWF  
 
KC® series  
Destiny® series  
(Tcoag, Ireland)  
Semi; full  Mechanical  
Chromogenic  
Immunologic  
aPTT, TT, Anti-Xa, Fibrinogen, PT  
 
Tables
Table 2: Classification of commercially available coagulation POC devices based on their endpoint detection method 
Type of detection Device (Manufacturer) Volume 
(µl) 
Type of 
withdrawal 
Comments 
Optical 
Hemochron® Signature +, 
Signature Elite (ITC, USA) 
15 Fingerstick 
Venipuncture 
Change in fluid oscillation 
PT; ACT; aPTT – multiparametric tests 
User friendly; quantitative; small sample volume; 
handheld/portable; self contained waste channel 
 
Cascade POC (Helena 
Laboratories Point of care, USA) 
35 Fingerstick 
Venipuncture 
Superparamagnetic oxide particles  
PT; ACT; aPTT; Enox 
Small sample volume; handheld/portable 
 
ProTime® Microcoagulation 
System (ITC, USA) 
~25 Fingerstick Blood is pumped through the channels  
PT/INR 
Stores patient data; onboard and external quality controls; 
user friendly; handheld/portable 
 
Coag-Sense™ PT/INR Monitoring 
System (CoaguSense Inc., USA) 
10 Fingerstick Mechanical principle 
PT/INR 
Small sample volume; disposable strip; handheld/portable 
 
GEM®PCL  Plus (Instrumentation 
Laboratory, USA) 
~50 Fingerstick for 
PT only 
Change in fluid oscillation in a test channel 
PT; ACT; aPTT 
Handheld/portable; maintenance free; automated 
measuring and mixing; customised programming options  
 
microINR® (iLine Microsystems, 
Spain) 
3 Fingerstick Microcapillary cessation of flow 
PT/INR 
Handheld/portable; user friendly; fully automatic 
 
 
 
Hepcon® HMS Plus™ Hemostasis 
Management System (Medtronic 
Cardiac Surgery, USA) 
 
2,500-
3,000 
 
Venipuncture POC benchtop analyzer 
Heparin dose; heparin protamine titration; ACT 
Disposable cartridges; user friendly operation; storage 
and data download options 
 
Bio-AMD’s COAG (Bio-
Alternative Medical Devices Ltd., 
UK) 
 
- Fingerstick Optical-magnetic detection principle 
PT/INR 
Small simple volume; rapid results; USB connection for 
data output; internal memory 
 
Electro- 
mechanical 
ACT Plus
™ 
System (Medtronic 
Cardiac Surgery, USA) 
400-800 Venipuncture POC benchtop analyzer 
Low and high range ACT 
External data management software; unsuitable patient 
self use 
 
Hemochron® Response (ITC, 
USA) 
400 -2,000 Venipuncture 
Fingerstick 
Change in magnet position 
PT; ACT; aPTT; TT; HiTT; heparin response; protamine 
response 
Gold standard testing technology; dual testing 
capabilities; data management function; portable 
 
Actalyke® XL (Helena 
Laboratories Point of care, USA) 
500 Venipuncture Two-point soft-clot detection 
ACT 
Portable; dual well testing; reproducible; good data 
handling 
 
Actalyke® Mini II (Helena 
Laboratories Point of care, USA) 
500 Venipuncture Two-point clot detection 
ACT 
Portable; sensitive; high visibility screen; inexpensive 
 
Thrombotrack™ Select 2 (Axis-
Shield, Norway) 
15-100 Fingerstick 
Venipuncture 
2 measurement channels 
PT; ACT; aPTT; Fibrinogen  
Automatic start upon reagent addition; input of reagent 
specific data 
 
Thrombotrack™ Solo (Axis-
Shield, Norway) 
25-100 Fingerstick 
Venipuncture 
1 measurement channel 
PT; ACT; aPTT; Fibrinogen 
Software system controls reaction procedure 
 
CoagLite® & CoagMax® 
(Microvisk Technologies, UK) 
5 Fingerstick 
Venipuncture 
MEMS technology 
PT/INR 
Handheld/portable ; in-built quality control checks; data 
upload option via USB connection 
 
Electro- 
chemical 
i-STAT® (Abbott Point of care 
Inc., USA) 
 
 
 
INRatio®/INRatio2® PT INR 
Monitor (Alere, USA)  
 
17- 95 
 
 
 
 
~15 
 
Fingerstick 
Venipuncture 
 
 
 
Fingerstick 
Electrogenic 
PT/INR; ACT 
Handheld/portable; rapid results; data upload to patient 
chart; easy to use 
 
Changes in impedance 
PT/INR 
Handheld/portable; large LCD; internal quality controls; 
individually wrapped strips for storage at room 
temperature; rapid results 
 
CoaguChek® XS, CoaguChek® 
XS Plus and XS Pro  PT Test 
System 
(Roche Diagnostics, USA) 
8 Fingerstick 
Venipuncture 
Amperometric detection 
PT/INR 
Handheld/portable; on board quality control; battery 
powered; patient/operator identification 
    
Table 3. Current potential most commonly used POC devices for platelet function and antiplatelet 
therapy analysis 
Type of 
detection 
Device (Manufacturer) Sample type Volume 
(µl) 
Platelet 
Function 
Device 
Optical 
 
 
 
 
 
VerifyNow® (Accumetrics, USA) *CWB <1,000 Genuine POC 
 
Impact® Cone and Plate(let) 
Analyser (Matis Medical Inc., 
Belgium) 
 
*CWB ~130 POC 
Electrical 
impedance 
 
 
 
 
 
 
 
Plateletworks® (Helena 
Laboratories Point of care, USA) 
 
 
*CWB 1,000 POC 
Multiplate® (Roche Diagnostics, 
Switzerland) 
Hirudin or 
heparin 
anticoagulated 
WB 
 
300 POC 
Change in 
pressure 
 
 
PFA-100® (Siemens Healthcare 
Diagnostics, 
Inc., USA) 
 
 
 
*CWB 
 
 
800 
 
 
POC 
Electro-
mechanical 
 
TEG® Platelet Mapping™ 
System (Haemonetics, USA) 
Heparin 
anticoagulated 
WB 
small POC 
*CWB = Citrated Whole Blood 
 Table 4: Novel research methodologies and technologies in coagulation testing  
New method Characteristics Sensitivity/accuracy Application 
 
Reference 
Amperometric biosensor 
for thrombin generation 
 
 
 
Flow front position 
and/or velocity-based 
clotting time device  
 
 
 
 
 
 
Lateral flow chip for 
measuring fibrinogen 
levels 
 
 
 
 
Quartz crystal 
microbalance (QCM) 
system for platelet 
aggregation 
 
 
Single use 
Electrochemical sensor 
10 µl sample 
 
 
Disposable strip 
Laminated polymeric chip 
Capillary flow 
Optical detection 
LED illumination 
3 µl sample 
<1 minute results 
 
 
Lateral flow 
Zeonor 
Visual measurement 
15 µl sample 
5 minute result 
 
 
Electrochemical transducer 
Piezoelectric AT-cut α-quartz 
Gold electrodes 
180-225 µl 
0.4-50 U/mL thrombin 
 
 
 
 
Sample flow monitoring 
correlates well with clotting time 
 
 
 
 
 
 
 
1-7g/L fibrinogen 
 
 
 
 
 
 
Frequency shifts correlate well 
with % aggregation 
 
Thrombin generation  
Hemostatic function 
 
 
 
PT/INR measurements 
for warfarin monitoring 
 
 
 
 
 
 
 
Fibrinogen determination 
Cardiovascular disease 
risk 
 
 
 
 
Platelet aggregation 
Cardiopulmonary bypass 
 
 
 
[36] 
 
 
 
 
[62] 
 
 
 
 
 
 
 
 
[63] 
 
 
 
 
 
 
[64] 
Aptamer-based Polymer chip 10 ng/mL thrombin Thrombin measurement [65] 
microfluidic chip for 
thrombin detection using 
magnetic beads and 
quantum dots 
 
 
Microfluidic device for 
platelet aggregation 
using micro-gradients in 
flowing blood 
 
 
Microstructured lateral 
flow chip for fluorescent 
detection of clot 
formation 
 
 
Microfluidic impedance 
cytometer for platelet 
analysis 
 
Pumping 
Magnetic beads and quantum 
dots 
Fluorescence 
 
 
Polydimethylsiloxane chip 
200 µl sample 
Epi-fluorescence imaging 
 
 
 
Lateral flow chip 
Zeonor chip 
25 µl sample 
Fluorescence 
 
 
Pressure sensitive adhesive 
chip with platinum electrodes 
Dielectric focusing 
Differential impedance 
Spectroscopy 
Frequencies of 280 kHz- 4 
MHz 
Syringe pumping 
 
 
 
 
 
 
 
Precise control over location of 
forming aggregates 
 
 
 
 
0-2 U/mL heparin 
Linearity (R
2
 = 0.99) 
 
 
 
 
Distinguishes between resting 
and active platelets 
Distinguishes between red blood 
cells and platelets 
 
 
 
 
 
 
Platelet aggregation 
 
 
 
 
 
Heparin monitoring 
 
 
 
 
 
Platelet activation 
 
 
 
 
 
 
 
[66] 
 
 
 
 
 
[67] 
 
 
 
 
 
[68] 
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